
Your Feed
Factors Influencing Enrollment in Hematologic Cancer Trials (2008-2023) | Rupayan Kundu, MD | #ASH24
Barriers to Stem Cell Transplant in #AML: NC Cohort Insights | Michele Sainvil, MD | #ASH24
Barriers to Stem Cell Transplant in #AML: NC Cohort Insights | Michele Sainvil, MD | #ASH24
ASH 2024 Wrap-Up: What's next in #Myeloma Treatment | Claudio Cerchione, MD | #ASH24
ASH 2024 Wrap-Up: What's next in #Myeloma Treatment | Claudio Cerchione, MD | #ASH24
ISB 2001 in Relapsed/Refractory #Myeloma: Phase 1 Results | Hang Quach, MD, Cyril Konto, MD | #ASH24
ISB 2001 in Relapsed/Refractory #Myeloma: Phase 1 Results | Hang Quach, MD, Cyril Konto, MD | #ASH24
TP53-Mutated AML & MDS: Why Clinical Trials Are Your Best Option | Dan Link, MD | #ASH24
TP53-Mutated AML & MDS: Why Clinical Trials Are Your Best Option | Dan Link, MD | #ASH24
Adding Menin Inhibitors in Combination Therapy for AML Patients | Amir Fathi, MD | #ASH24
Adding Menin Inhibitors in Combination Therapy for AML Patients | Amir Fathi, MD | #ASH24
Promising Early Results from Menin Inhibitors for Treating AML | Harry Erba, MD | #ASH24
Promising Early Results from Menin Inhibitors for Treating AML | Harry Erba, MD | #ASH24




